Anti-PHLB2/ PHLDB2/ LL5b monoclonal antibody

Anti-PHLB2/ PHLDB2/ LL5b antibody for FACS & in-vivo assay

Target products collectionGo to PHLDB2/PHLDB2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1363-Ab-1/ GM-Tg-hg-MP1363-Ab-2Anti-Human PHLDB2 monoclonal antibodyHuman
GM-Tg-rg-MP1363-Ab-1/ GM-Tg-rg-MP1363-Ab-2Anti-Rat PHLDB2 monoclonal antibodyRat
GM-Tg-mg-MP1363-Ab-1/ GM-Tg-mg-MP1363-Ab-2Anti-Mouse PHLDB2 monoclonal antibodyMouse
GM-Tg-cynog-MP1363-Ab-1/ GM-Tg-cynog-MP1363-Ab-2Anti-Cynomolgus/ Rhesus macaque PHLDB2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1363-Ab-1/ GM-Tg-felg-MP1363-Ab-2Anti-Feline PHLDB2 monoclonal antibodyFeline
GM-Tg-cang-MP1363-Ab-1/ GM-Tg-cang-MP1363-Ab-2Anti-Canine PHLDB2 monoclonal antibodyCanine
GM-Tg-bovg-MP1363-Ab-1/ GM-Tg-bovg-MP1363-Ab-2Anti-Bovine PHLDB2 monoclonal antibodyBovine
GM-Tg-equg-MP1363-Ab-1/ GM-Tg-equg-MP1363-Ab-2Anti-Equine PHLDB2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1363-Ab-1/ GM-Tg-hg-MP1363-Ab-2; GM-Tg-rg-MP1363-Ab-1/ GM-Tg-rg-MP1363-Ab-2;
GM-Tg-mg-MP1363-Ab-1/ GM-Tg-mg-MP1363-Ab-2; GM-Tg-cynog-MP1363-Ab-1/ GM-Tg-cynog-MP1363-Ab-2;
GM-Tg-felg-MP1363-Ab-1/ GM-Tg-felg-MP1363-Ab-2; GM-Tg-cang-MP1363-Ab-1/ GM-Tg-cang-MP1363-Ab-2;
GM-Tg-bovg-MP1363-Ab-1/ GM-Tg-bovg-MP1363-Ab-2; GM-Tg-equg-MP1363-Ab-1/ GM-Tg-equg-MP1363-Ab-2
Products NameAnti-PHLDB2 monoclonal antibody
Formatmab
Target NamePHLDB2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-PHLDB2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species PHLB2/ PHLDB2/ LL5b VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1363
    Target NamePHLDB2
    Gene ID90102,208177,685611,709353,478560,101086338,509784,100071564
    Gene Symbol and SynonymsC820004H04Rik,LL5b,LL5beta,PHLDB2
    Uniprot AccessionQ86SQ0
    Uniprot Entry NamePHLB2_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000144824
    Target ClassificationN/A

    The target: PHLDB2, gene name: PHLDB2, also named as LL5b, LL5beta. Enables cadherin binding activity. Involved in several processes, including negative regulation of focal adhesion assembly; regulation of cytoskeleton organization; and regulation of embryonic development. Located in several cellular components, including basal cortex; cell leading edge; and intermediate filament cytoskeleton. Colocalizes with focal adhesion. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.